Table 2.
Log Rank Test of CRPC-Related Risk Factors in Whole Cohort
| Variables | N | HR (95% CI) | P-value |
|---|---|---|---|
| PSA at diagnosis | |||
| <20 ng/mL | 18 | 1 | 0.042 |
| ≥20 ng/mL | 40 | 3.36 (1.043–10.75) | |
| Positive cores of biopsy | |||
| <50% | 21 | 1 | 0.311 |
| ≥50% | 37 | 1.812 (0.574–5.714) | |
| Gleason grade groups | |||
| 1 to 4 | 50 | 1 | <0.0001 |
| 5 | 8 | 47.52 (7.856–287.4) | |
| Clinical T stage | |||
| cT1c to 3a | 35 | 1 | 0.005 |
| cT3b to 4 | 23 | 5.618 (1.694–18.52) | |
| PSA nadir (ng/mL) | |||
| <0.05 | 40 | 1 | <0.0001 |
| ≥0.05 | 18 | 24.46 (6.800–87.95) | |
| ALK level at diagnosis | |||
| 0–125 ng/mL | 15 | 1 | 0.855 |
| >125 ng/mL | 43 | 1.117 (0.339–3.680) |
Abbreviations: CRPC, castration-resistant prostate cancer; ALK, alkaline phosphatase.